Article
Integrated Biosciences’ new platform has potential to fuel advances in senolytic anti-aging compounds and longevity research AI-driven platform built on work pioneered at MIT identifies three candidates with comparable efficacy and superior medicinal chemistry relative to current investigational compounds Treatment of aged mice reduced number of senescent ‘zombie’ cells and lowered expression of senescence-associated genes…
Read More
Excerpt from the Press Release: SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK…
Read More
– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date – – Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the…
Read More
Excerpt from the Press Release: NATICK, Mass. and QUINCY, Mass., April 26, 2023 /PRNewswire/ — Avenge Bio, Inc. (“Avenge”), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the successful completion of the first dose cohort in a Phase…
Read More
Excerpt from the Press Release: BOSTON, April 27, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its…
Read More
Baptist Health Cancer Care Abstract to be presented at Oncology Nursing Society Annual Symposium Excerpt from the Press Release: NORWOOD, Mass., April 27, 2023 /PRNewswire/ — Entrinsic Bioscience is pleased to announce the upcoming poster session on the role of Enterade® Advanced Oncology Formula in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment. The…
Read More
Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies…
Read More
Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of human ABCA4 protein using a single subretinal dose of DNA payload Excerpt from the Press Release: CAMBRIDGE, Mass., April 20, 2023 /PRNewswire/ — Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today that Gayathri Ramaswamy, Ph.D., Vice President, Drug Discovery…
Read More
Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FRα-1: A Study to Evaluate ELU001, a C’Dot Drug…
Read More
Excerpt from the Press Release: PRINCETON, N.J., April 21, 2023 /PRNewswire/ — Oblato, Inc. (the Company), a subsidiary company of HLB Therapeutics in Korea, has announced today the first enrollment for recurrent high-grade glioma patients in a Phase 1 clinical trial in the USA with an oral formulation of its proprietary compound OKN-007. This is…
Read More